Prostate cancer · Oligorecurrent bone-metastatic HSPC · SABR ± radium-223

RAVENS

Does radium-223 added to SABR delay progression in recurrent bone-metastatic HSPC?

Randomized phase II; n=64; at least one bone metastasis. SABR vs SABR+6 cycles radium-223.

Trial design

Randomized phase II; n=64; at least one bone metastasis. SABR vs SABR+6 cycles radium-223.

Outcome visualization · source-reported data

Adjusted HR 1.42 (95% CI 0.79–2.56); p=0.24

SABR alone

11.8 months SABR

SABR + Ra-223

10.5 months + Ra-223

Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.

No PFS improvement with added radium-223; grade 3 treatment-related events were 6% vs 17%.

https://pubmed.ncbi.nlm.nih.gov/40334149/

undefined